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Anterior Pituitary Hypoplasia and Dwarfism
in Mice Lacking the Dopamine Transporter
Roger BosseÂ ,² Fabio Fumagalli,²³ Mohamed Jaber, (GHRH) not only regulates GH secretion, but it also con-
trols proliferation and survival of somatotrophs (Guil-Bruno Giros, Raul R. Gainetdinov, William C. Wetsel,*
Cristina Missale, and Marc G. Caron lemin et al., 1982; Rivier et al., 1982; Barinaga et al.,
1983; Billestrup et al., 1986). The importance of thisHoward Hughes Medical Institute Laboratories
Departments of Cell Biology, Medicine action is such that a mutation in the GHRH receptor
gene can lead to somatotroph hypoplasia and dwarfismand *Psychiatry and Behavioral Sciences
Duke University Medical Center (Lin et al., 1993). Moreover, there is now increasing evi-
dence that resident growth factors can provide furtherDurham, North Carolina 27710
local control of pituitary development (Borrelli et al.,
1992; McAndrew et al., 1995). By contrast, very little
is known about the influence of the hypothalamus onSummary
pituitary ontogeny. Hypothalamic dopamine (DA) is a
major modulator of specific pituitary functions. DA se-Deletion of the dopamine transporter (DAT) results in
increased dopaminergic tone, anterior pituitary hypo- creted from tuberoinfundibular neurons is carried in the
plasia, dwarfism, and an inability to lactate. DAT elimi- hypophysial portal blood to the anterior pituitary where
nation alters the spatial distribution and dramatically it inhibits PRL synthesis and secretion (Ben-Jonathan,
reduces the numbers of lactotrophs and somato- 1985). Tuberohypophysial dopaminergic neurons pro-
trophs in the pituitary. Despite having normal circulat- ject directly to the intermediate lobe of the pituitary
ing levels of growth hormone and prolactin in blood, (Bjorklund et al., 1973), where they inhibit the synthesis
hypoplastic glands from DAT2/2 mice fail to respond and release of a-melanocyte-stimulating hormone
to secretagog stimulation. The effects of DAT deletion (a-MSH) (CoteÂ et al., 1982; Stack and Surprenant, 1991).
on pituitary function result from elevated DA levels While the role of DA in the control of pituitary hormone
that down-regulate the lactotroph D2 DA receptors and secretion is well established, the possibility that the
depress hypothalamic growth hormone-releasing hor- dopaminergic hypothalamopituitary axis may affect dif-
mone content. These results reveal an unexpected and ferentiation, proliferation, and survival of pituitary cells
important role or DA in the control of developmental during development has never been investigated.
events in the pituitary gland and assign a critical role Termination of the action of DA is primarily achieved
for hypothalamic DA reuptake in regulating these by its reuptake via the dopamine transporter (DAT) lo-
events. cated on the plasma membrane of DA-secreting cells.
Consequently, the DAT plays a critical role in the regula-
tion of temporal and spatial functions of DA (Amara
Introduction and Kuhar, 1993; Giros and Caron, 1993). Although this
transporter is expressed on hypothalamic dopaminergic
The anterior pituitary is composed of five different endo- neurons (Garris and Ben-Jonathan 1991; Meister and
crine cell types. These cells arise in a precise temporal Elde, 1993), the relevance of DA reuptake in calibrating
and spatial order during development, and this pattern DA overflow to the anterior pituitary remains enigmatic.
is regulated by transcription factors and hormones. So- Recently, homologous recombination was used to
matotrophs and lactotrophs originate from a common create a mouse strain lacking the DAT gene (Giros et
committed progenitor cell (Osamura and Watanabe al., 1996). Mice homozygous for this deletion are hyper-
1985; Voss and Rosenfeld, 1992) under the influence of active due to the protracted duration of DA action at
the POU domain Pit-1/GHF1 transcription factor, which dopaminergic synapses. These mice also display pro-
is expressed in the developing anterior pituitary from found adaptive biochemical changes in their attempts
embryonic day 14 (Bodner and Karin, 1987; Ingraham to dampen this increased neurotransmission (Giros et
et al., 1988; Nelson et al., 1988; Castrillo et al., 1989; al., 1996; Jones et al., unpublished data). Two striking
Mangalam et al., 1989; DolleÂ et al., 1990). The require- properties of mice lacking the DAT point to a possible
ment of the Pit-1/GHF1 signal for both the development dysfunction of the hypothalamopituitary axis. First, fe-
and maintenance of normal growth hormone (GH)-, pro-
males lacking the DAT show an impaired capability to
lactin (PRL)-, and thyroid-stimulating hormone (TSH)-
nurse their young. Second, these animals are signifi-
producing cells is clearly shown by the complete ab-
cantly growth retarded postnatally compared to their
sence of these cell types in inherited dwarfism resulting
wild-type littermates (Giros et al., 1996). Thus, mice lack-
from mutations in the Pit-1/GHF1 gene (Li et al., 1990;
ing the DAT appear to be a valuable model to investigate
Castrillo et al., 1991; Pfaffle et al., 1992; Radovick et al.,
how DA can influence pituitary development.
1992). Besides transcription factors, certain hypotha-
In the present study, we show that deletion of the
lamic hormones have been implicated in pituitary ontog-
DAT gene results in a remarkably increased DA turnover
eny. Hypothalamic growth hormone-releasing hormone
in both the hypothalamus and pituitary. Therefore, the
DAT knockout model demonstrates, in an unequivocal²These authors contributed equally to this work.
way, that DA reuptake through the transporter plays a³Fabio Fumagalli is a visiting fellow from Center of Neuropharmacol-
critical physiological role in the regulation of hypo-ogy, Institute of Pharmacological Sciences, University of Milan, Via
Balzaretti 9, 20133 Milano, Italy. physiotrophic dopaminergic function. In addition, this
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model reveals a novel pathway regulating pituitary de- al., 1978; Enjalbert and Bockaert, 1983; Ben-Jonathan,
1985), and it may explain the decreased lactation ofvelopment, through dopaminergic control of the num-
bers of functionally diverse cell phenotypes. First, we DAT2/2 mothers. However, the remarkable hypopituitar-
ism and the dwarfism of mice lacking the DAT point todemonstrate that hypothalamic GHRH expression is un-
der inhibitory dopaminergic control because deletion of the existence of a defect in pituitary development and
to a possible dysfunction of the GH and PRL axes.the DAT gene results in a substantial decrease of GHRH
expression. Second, overstimulation of pituitary D2 re-
ceptors in the absence of DAT leads to decreased ex- Neurochemical Changes in the Hypothalamus
pression of the Pit-1/GHF1 gene in the adult gland. As and Pituitary Gland Substantiate the Importance
a result, the anterior pituitary of mice lacking the DAT of the DAT in the Neuroendocrine Actions of DA
is hypoplastic due to a selective loss of somatotrophs DA released from the tuberoinfundibular neurons is
and mammotrophs. A previously unappreciated major transported via the hypophysial portal system to the
physiological role of DA is thus the inhibitory regulation anterior pituitary. While it is generally assumed that the
of the molecular and cellular events necessary to gener- levels of DA reaching the pituitary are a direct reflection
ate and maintain the full complements of mature lacto- of the released DA, recent evidence indicates that the
trophs and somatotrophs during pituitary development. DAT is expressed, albeit at low levels, on the hypotha-
The importance of this action is such that the increased lamic dopaminergic neurons. However, direct evidence
dopaminergic transmission in theabsence of DAT brings for a physiological role of hypothalamic DAT is still lack-
about dwarfism and a failure to lactate. ing (Meister and Elde, 1993). Measurements of DA and
its metabolites in the hypothalamus of DAT2/2 mice by
high pressure liquid chromatography (HPLC)±electro-Results
chemical detection indicated that tissue DA content was
slightly decreased (by 30%) while the DOPAC/DA andDeficits in Lactation and Somatic Growth
HVA/DA ratios were increased 1.4- and 3-fold, respec-in DAT2/2 Mice Point to Dysfunction
tively, compared to wild-type mice (Table 1). Althoughof the Hypothalamopituitary Axis
we did not measure directly extracellular levels of DAThe first overt phenotype observed in DAT2/2 animals
in hypothalamus, the fact that in the striatum of DAT2/2was the inability of females to lactate postpartum. Con-
mice dramatically increased DA turnover was accompa-sequently, high rate survival of newborns could only be
nied by markedly elevated extracellular DA levels (Jonesachieved by fostering them towild-type nursing mothers
et al., unpublished data) led us to suggest that these(Giros et al., 1996). Second, all DAT2/2 mice exhibited
changes reflect increased extracellular DA concentra-a dwarf phenotype (Figure 1a). At birth and on the first
tions. In parallel, pituitary content of DA was similarlydays of postnatal life, body weights of the DAT2/2 mice
decreased (by 35%), but both DOPAC/DA and HVA/DAdid not differ appreciably from their wild-type or hetero-
ratios were dramatically increased (5.5- and 9.4-fold,zygous littermates. However, DAT2/2 mice displayed a
respectively) in DAT2/2 mice (Table 1), suggesting anmuch slower growth rate as neonates until adulthood
even greater increase of extracellular DA levels in the(Giros et al., 1996); a property reminiscent of previously
pituitary gland. These data provide evidence, albeit indi-characterized dwarf mice with defective pituitary func-
rect, for increased DA supply to the anterior pituitarytion (Li et al., 1990; Lin et al., 1993). Differences in weight
and suggest that DAT plays a previously unappreciatedof homozygous and wild-type mice were apparent within
pivotal role in calibrating the dopaminergic activity of1 week of age and by postnatal week 8 where DAT2/2
the hypothalamopituitary axis.mice displayed a 44% reduction in weight compared to
In concert with these observations are the data ob-wild-type littermates. Both sexes were affected. Evalua-
tained by direct ligand binding on pituitary membranetion of skeletal growth revealed a significant reduction
preparations (Figure 2, left panel) and pituitary sectionsin the length of long bones (data not shown).
(Figure 2, right panel). Here, the number of D2 receptorExamination of pituitary glands revealed a pro-
binding sites was markedly decreased (75%) in DAT2/2nounced hypopituitarism in DAT2/2 mice that selectively
mice. Such an extensive down-regulation of D2 recep-involves the anterior and intermediate lobes of the pitu-
tors likely represents an adaptive change to the in-itary, but not the posterior lobe (Figure 1b). This differ-
creased DA overflow to the gland in the absence of DAT.ence presumably reflects both the differential develop-
mental origin and hormonal regulation of the posterior
lobe compared to the other two lobes (Voss and Rosen- Defective Development of Anterior Pituitary
Gland in DAT2/2 Animalsfeld, 1992). Evaluation of pituitary weight indicated that
the hypoplastic glands are about half the size of normal Examination of the distribution of PRL in the pituitary
by in situ hybridization revealed a dramatic decrease ofglands both at 4 and 8 weeks of age (Figure 1c). Interest-
ingly, from the fourth to the eighth week of age, the its mRNA in DAT2/2 animals (Figures 3a and 3b). In wild-
type pituitary glands, the intensity of the signal waspituitaries developed at the same rates in DAT2/2 and
wild-type mice (pituitary weights increased 1.9- and 1.8- gradually distributed from the anterolateral to the cau-
domedial part of the anterior lobe, reflecting the normalfold in wild-type and in DAT2/2 mice, respectively). This
observation suggests that the defect leading to hypopi- distribution of pituitary lactotrophs (Osamura and Wata-
nabe, 1985; Voss and Rosenfeld 1992; Lin et al., 1993).tuitarism occurs early during pituitary development.
The inhibitory action of DA on PRL synthesis and In contrast, in DAT2/2 pituitaries, the PRL signal was
still present in theanterolateral gland but virtually absentsecretion has been documented previously (Caron et
Role of Dopamine in Pituitary Cell Lineage Development
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Figure 1. Body Size, Pituitary Gland Morphology, and Weight of Wild-Type and Homozygous DAT2/2 Mice
(a) Comparison of the size of 8-week-old animals. The average weight of wild-type mice was 30 g 6 0.8 (n 5 12) and DAT2/2 mice was 17 g 6
0.6 (n 5 17).
(b) Gross morphology of pituitary glands. DAT2/2 mice have a marked reduction in the size of both the anterior (A) and intermediate (I) lobes,
with no obvious changes in the size of the posterior (P) lobe.
(c) Reduction in weight of DAT2/2 pituitaries at the time of weaning (4 weeks) and as adults (8 weeks). Scale bars represent the mean 6 SEM
of four glands of DAT2/2 and five glands of wild-type mice. **P , 0.001 versus 4- or 8-week-old wild-type mice (Student's t-test).
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Table 1. Hypothalamic and Pituitary Levels of DA and Its Metabolites in Wild-Type and DAT2/2 Mice
Hypothalamus Pituitary
DOPAC/DA HVA/DA DOPAC/DA HVA/DA
1/1 0.30 6 0.02 0.30 6 0.03 0.42 6 0.04 0.14 6 0.01
2/2 0.43 6 0.03** 0.90 6 0.11** 2.32 6 0.68** 1.31 6 0.43**
DA and its metabolites were measured in the hypothalamic and pituitary homogenates by HPLC-EC. In the hypothalamus, DA levels were
0.73 6 0.04 ng/mg wet tissue in wild-type mice and 0.51 6 0.03 ng/mg wet tissue in DAT2/2 mice. In the pituitary, DA levels were 0.36 6 0.02
ng/mg wet tissue in wild-type mice and 0.23 6 0.06 ng/mg wet tissue in DAT2/2 mice. Results are the mean 6 SEM of six animals for each
genotype.
** P , 0.001 versus wild-type mice (Student's t-test).
in the rest of the gland (Figures 3a and 3b). Similarly, must chronically deplete their stores of pituitary GH and
PRL to maintainplasma hormone levels within thephysi-determination of GH mRNA in DAT2/2 pituitaries re-
vealed a decrease in the hybridization signal with a vir- ological range. Administration of secretagogs, however,
failed to increase either PRL or GH plasma levels intual loss of the normal anterolateral to caudomedial dis-
tribution of the hormone (Figures 3c and 3d). By DAT2/2 mice. In particular, blockade of pituitary D2 re-
ceptors by a full effective dose of (2)sulpiride producedcomparison, in situ hybridization studies with a-GSU
(Figures 3e and 3f), the common subunit of TSH, luteiniz- a 4-fold increase of plasma PRL levels in wild-type mice
butdid not modify plasmaPRL in DAT2/2 animals (Figureing hormone, and follicle-stimulating hormone, or with
b-TSH (Figures 3g and 3h) revealed no changes in the 4a). Similarly, the clonidine±dexamethasone combina-
tion led to a robust stimulation of GH secretion in wild-expression and distribution of these hormones. These
data suggest that thyrotrophs and gonadotrophs were type but not in the DAT2/2 mice (Figure 4b). Thus, the
decreased hormone content of theDAT2/2 glands corre-not affected by the DAT deletion and that the pituitary
hypoplasia observed is not due to panhypopituitarism. lates well with the relative lack of hormone-secreting
cells revealed by histological means. The lack of respon-Instead, the absence of DAT appears to specifically and
selectively reduce both the density and distribution of siveness of DAT2/2 pituitaries to secretagogs is more
intriguing and may reflect the occurrence of adaptivethe lactotrophs and somatotrophs in the pituitary. More-
over, our data suggest that DAT ablation results in a changes to levels of the D2 DA receptor or GHRH, which
regulate, respectively, PRL and GH secretion.substantial alteration in the mechanisms that dictate
proliferation, migration, and/or maintenance of lacto- Increased plasma levels of PRL consequent to a
change in the hypothalamic release of DA and/or othertrophs and somatotrophs during development.
factors at the time of parturition are required for mam-
mary gland maturation and milk production. Similarly,Impairment of Anterior Pituitary Gland
Function in DAT2/2 Animals pulsatile release of GH in response to GHRH and so-
matostatin (SST) is required for somatic growth (Muller,In an attempt to examine how the deficits in histological
parameters may be correlated with the function of the 1987). Despite normal circulating PRL and GH levels in
DAT2/2 mice, the hypoplastic pituitaries cannot producegland, we measured the pituitary content and plasma
levels of both PRL and GH under basal and stimulated and secrete sufficient quantities of PRL and GH to sup-
port lactation and normal growth.conditions. The pituitary contents of both PRL and GH
were greatly decreased in DAT2/2 mice (PRL, 85%; and
GH, 70%) (Figures 4a and 4b). Nevertheless, plasma Pit-1/GHF1 Expression in DAT2/2 Hypopituitarism
One possible explanation for the anterior pituitary de-levels of both PRL and GH were similar in DAT2/2 and
wild-type animals. Thus, it appears that DAT2/2 mice fects of DAT2/2 mice could be due to down-regulation
Figure 2. D2 DA Receptor Content in Pituitar-
ies of Wild-Type and DAT2/2 Mice
Quantitation of [125I]-NCQ 298 binding to
whole pituitary gland homogenates (left
panel) or pituitary frontal sections as deter-
mined by autoradiography (right panel) was
performed as described under Experimental
Procedures. Each bar represents the mean
6 SEM of seven glands per genotype. *P ,
0.05, and **P , 0.01 versus wild type (Stu-
dent's t-test).
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Figure 3. mRNA Levels of PRL and GH in
Wild-Type and DAT2/2 Pituitary Glands
Dark-field photomicrographs (350) (a±d) of
PRL ([a] and [b]) and GH ([c] and [d]) mRNA
are shown. The positions of the anterior (a)
and intermediate (i) lobes are noted. Experi-
ments were performed as described under
Experimental Procedures using six animals
pergenotype. Representative data are shown
in each panel. In situ hybridization signals
reveal that both PRL and GH levels are de-
creased with a relative loss of the anterolat-
eral to caudomedial gradient in DAT2/2 mice
compared to wild-type animals.
(e±h) Autoradiographic images of a-GSU ([e]
and [f]) and b-TSH ([g] and [h]) mRNA hybrid-
ization signals in the pituitaries of wild-type
and DAT2/2 mice. These experiments re-
vealed no differences in a-GSU or b-TSH
gene expression between the two genotypes.
of the Pit-1/GHF1 gene. Pit-1/GHF1 is involved both Mangalam et al., 1989; DolleÂ et al., 1990). Examination
of Pit-1/GHF1 expression at embryonic day 16.5 re-developmentally and postnatally in the establishment
and maintenance of PRL- and GH-secreting cells, and vealed no differences between wild-type and DAT2/2
embryos (Figure 5, top panel). This lack of changes ofin the expression of these hormone genes (Bodner and
Karin, 1987; Ingraham et al., 1988; Nelson et al., 1988; Pit-1/GHF1 expression correlates with the observation
Neuron
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Figure 4. PRL and GH Pituitary Content and
Responsiveness to Secretagogs in Wild-Type
and DAT2/2 Animals
Pituitary and serum levels of PRL (a) and GH
(b) were measured by RIA in 8-week-old mice
as described under Experimental Proce-
dures. PRL and GH release were evoked us-
ing either (2)sulpiride (30 mg/kg) or clonidine
(250 mg/kg)±dexamethasone (10 mg/kg), re-
spectively. Each bar represents the mean 6
SEM of 3 animals for pituitary hormone con-
tent and 12 animals for plasma hormone con-
centrations. Note the prominent decrease in
pituitary hormone content and the failure of
the gland to respond to appropriate secre-
tagogs. *P , 0.05 versus saline-treated wild-
type mice; **P , 0.01 versus wild-type mice
(Student's t-test).
that somatotrophs and lactotrophs are still present in down-regulation in the expression of this transcription
factor in the remaining cells cannot be excluded.the mutant mice, albeit in a much reduced number. This
lack of changes in embryonic expression of Pit-1/GHF1
is also consistent with the apparently normal levels of
b-TSH mRNA, plasma TSH (53 6 10 ng/ml, n 5 5; and GH Dysfunction in DAT2/2 Mice Is Mediated by an
Action of DA at the Hypothalamic Level54 6 8 ng/ml, n 5 5 in wild-type and DAT2/2 mice,
respectively), and plasma thyroid hormones (T3 levels The proliferation and maintenance of somatotrophs in
the anterior pituitary, as well as GH release are underin wild-type were 124 6 8 ng/dl and DAT2/2 mice were
88 6 21 ng/dl; T4 levels in wild-type were 3.4 6 0.1 hypothalamic control. On the one hand, GHRH binds to
specific receptors on the surface of somatotrophs tomg/dl and DAT2/2 mice were 3.8 6 0.5 mg/dl). The normal
levels of the TSH and thyroid hormones suggest that promote their proliferation, and to stimulate GH synthe-
sis and secretion. On the other hand, SST inhibits GHthese hormones do not contribute to the somatic growth
phenotype. synthesis and secretion, and somatotroph proliferation
(Muller, 1987). Since the phenotype of DAT2/2 animals,A down-regulation of the Pit-1/GHF1 transcription fac-
tor at later stages of pituitary gland development could as well as the morphology of their pituitary glands are
reminiscent of the lit/lit dwarf mouse (Lin et al., 1993),contribute to the failure of proliferative and/or mainte-
nance mechanisms necessary to generate full comple- we investigated the status of both GHRH and SST in the
DAT2/2 dwarf animals. Northern blot analysis revealed aments of lactotrophs and somatotrophs in the adult
gland. As shown in Figure 5 (bottom panel), in situ hy- 55% reduction in the mRNA for hypothalamic GHRH
and a slight increase in the mRNA for SST in DAT2/2bridization revealed a 50% decrease in Pit-1/GHF1 ex-
pression in the anterior pituitary gland of adult DAT2/2 animals (Figure 6). These findings are further corrobo-
rated by the observation that hypothalamic content ofmice. The pattern of distribution of Pit-1/GHF1 through-
out the gland remained more diffuse than those of PRL GHRH is decreased by 43% in DAT2/2 mice (wild type:
142 6 11 pg/mg protein, n 5 6; heterozygotes 137 6and GH, and this could reflect, at least in part, the pres-
ence of this transcription factor in TSH-secreting cells. 17 pg/mg protein, n 5 13; and DAT2/2 82 6 6 pg/mg
protein, n 5 8). Taken together, these results demon-The decrease in Pit-1/GHF1 expression in DAT2/2 pitu-
itaries may also be related to the reductions in lacto- strate that hypothalamic expression and peptide con-
tent of these neurohormones are regulated by DA, andtrophs and somatotrophs. However, the possibility of a
Role of Dopamine in Pituitary Cell Lineage Development
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Figure 5. Pit-1/GHF1 mRNA Levels in Wild-
Type and DAT2/2 Mice
The upper panel represents pituitary expres-
sion of the Pit-1/GHF1 gene during mouse
development in wild-type and DAT2/2 mice.
Whole mouse embryos (day 16.5) were pro-
cessedas describedunder Experimental Pro-
cedures. The imageshown is a representative
autoradiogram. Five wild-type and three
DAT2/2 embryos were analyzed using 12±15
consecutive sections per embryo, and no sig-
nificant differences were detected between
the two genotypes. The lower panel repre-
sents dark-field photomicrographs (753) of
Pit-1/GHF1 mRNA in the pituitary of adult ani-
mals. The positions of the anterior (a) and
intermediate (i) lobes are noted. Experiments
wereperformed as described in Experimental
Procedures on eight animals per genotype,
and representative examples are shown. In
situ hybridization reveals that while Pit-1/
GHF1 was decreased by 50%, the distribu-
tion of the signal was uniform in DAT2/2 mice.
that increased dopaminergic transmission in the ab- and hypothalamic factors involved in pituitary ontogen-
esis have been identified, very little is known about thesence of DAT leads to a possible imbalance of this sys-
tem. The slight increase in SST might depress the re- influence of brain neurotransmitters on differentiation
and proliferation of the developing anterior pituitary.lease of GHRH (Yamauchi et al., 1991) and thereby inhibit
remaining somatotrophs from proliferating and produc- By using a mouse strain with constitutively increased
dopaminergic transmission due to the deletion of theing GH. This hypofunction of the hypothalamopituitary
GHRH axis could lead to hypopituitarism and dwarfism. DAT gene, we report novel evidence for the existence
of a new regulatory pathway of pituitary development.
In this case, DA appears to inhibit the proliferation and/Discussion
or maintenance of lactotrophs and somatotrophs. The
relevance of this action of DA is such that mice lackingPituitary development results in a temporally precise
appearance of five distinct cell types from an apparently the DAT manifest a pronounced hypopituitarism, due to
a combined hypoplasia of lactotrophs and somato-homogenous primordium. Between the time of organ
commitment and maturation, cell-type-specific prolifer- trophs. These actions result in dwarfism and an inability
to lactate.ation and terminal differentiation of distinct cell types
occur. While tissue-specific transcription factors that
are critical for the establishment of different pituitary cell The DAT in Tuberoinfundibular Neurons Plays
a Crucial Physiological Role in Calibratingphenotypes have been identified (Voss and Rosenfeld,
1992), the nature of extracellular signals that control DA Overflow to the Anterior Pituitary
The presence of DAT in hypothalamic neurons has beenproliferation and/or maintenance of pituitary cell lin-
eages remains elusive. In particular, while few hormones documented (Meister and Elde, 1993). However, its role
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in determining the extent of dopaminergic transmission
in the tuberoinfundibular system has been largely ig-
nored. It is generally believed in fact that, in contrast with
the other dopaminergic pathways where the reuptake of
most of the released DA limits the extent of transmission,
the clearance rate by the portal blood is the limiting step
in the control of DA supply to the anterior pituitary.
We demonstrate here that the reuptake of DA through
the DAT is crucial in maintaining a physiological and
calibrated regulation of pituitary function by hypotha-
lamic DA. As in the basal ganglia (Giros et al., 1996;
Jones et al., unpublished data), tissue content of DA
was diminished in the hypothalami and pituitaries of
DAT2/2 mice. Additionally, the ratios of metabolites to
DA, particularly HVA/DA, were elevated, reflecting the
presence of increased concentrations of extracellular
DA presumably due to the lackof reuptake. The substan-
tial down-regulation of D2 DA receptor numbers in the
anterior pituitary of mice lacking the DAT are consistent
with elevated levels of DA. These observations clearly
indicate that large amounts of DA reach the pituitary Figure 6. SST and GHRH Gene Expression in the Hypothalamus of
Wild-Type and DAT2/2 Micegland in the absence of DAT. The high levels of secreted
DA result in failure of homozygous females to lactate Northern blot experiments were performed as described under Ex-
perimental Procedures. Values for SST and GHRH mRNA were cal-postpartum.
culated relative to 28S rRNA as a control probe and are expressed
as the percentage of wild-type expression. Each bar is the mean 6
SEM of four to eight animals. Determinations were made in individualDAT Ablation Reveals a New Pathway for
8- to 9-week-old animals. **P , 0.002 versus wild-type (Student's
the Regulation of Pituitary Development t-test).
Mediated by DA
The idea that a dopaminergic mechanism could control
lactotroph proliferation has been suggested by the find-
in the median eminence only after birth (Gluckmann eting that D2 receptor agonists efficiently inhibit thegrowth
al., 1981). These observations further support the viewof PRL-secreting tumors in humans (Cunnah and Bes-
that DA likely influences proliferation, migration, and/orser, 1991). However, a physiological role for DA in the
maintenance of the somatolactotroph lineage early incontrol of pituitary cell lineage development has never
the postnatal life, when the expansion of the two cellbeen directly documented. Our data imply that DA plays
populations occurs (Voss and Rosenfeld, 1992). Thus,a major physiological role during development as an
DA presumably does not influence the generation of theinhibitor of proliferation and/or maintenance of not only
lactotroph and somatotroph phenotypes, but controlslactotrophs but also somatotrophs. Pituitaries of DAT2/2
the establishment of the functional complement of cellsmice showa selectivedecrease in theapparent numbers
from the already differentiated cells in postnatal life.of both somatotrophs and lactotrophs, and an alteration
Interestingly, rats with damaged hypothalamic dopa-in the distribution of the remaining cells. These cells
minergic neurons that escape DA control develop PRL-appear more in the anterolateral circumference of the
secreting tumors (Sarkar et al., 1982).gland where the stem cells are located, but are dimin-
ished in the caudomedial region of the anterior pituitary
where they normally reside (Voss and Rosenfeld, 1992; The Dopaminergic Control of Lactotroph
Development Implicates RegulationLin et al., 1993). The committed cells from which both
somatotrophs and lactotrophs originate first appear in of Intrapituitary Mechanisms
The effects of DA on lactotroph proliferation and/or sur-the pituitary on embryonic day 16 under the influence
of Pit-1/GHF1 (Ingraham et al., 1988; DolleÂ et al., 1990; vival likely occur at the pituitary level and are mediated
by D2 receptors. Ablation of the D2 receptor gene gener-Voss and Rosenfeld, 1992). The findings that expression
of Pit-1/GHF1 at embryonic day 16.5 is not modified in ates a mouse phenotype characterized by lactotroph
hyperplasia, hyperprolactinemia, and the developmentDAT2/2 mice and that GH- and PRL-positive cells are
present in the anterolateral segments of the adult ante- of PRL-secreting tumors in the adult animals (Saiardi
et al., 1997 [this issue of Neuron]). The evidence thatrior pituitary suggest that DA is unlikely to influence the
early developmental events that commit the pluripotent overstimulation of D2 receptors occurs in DAT2/2 mouse
pituitaries is substantiated by the marked down-regula-stem cells to generate specific cell types. Instead, de-
fects in the regulation of the process that maintains the tion (.70%) of these receptors (Figure 2). The extent of
this decrease in functional receptors may contribute tonormal complements of somatotrophs and lactotrophs
may be characteristic of the DAT2/2 mice. Studies of the lack of effect of D2 receptor antagonists on PRL
secretion in DAT2/2 mice. In the basal ganglia of micethe development of the hypothalamus and the hypotha-
lamopituitary axis indicate that in rodents DA first ap- where D2 receptors are down-regulated by z50%, func-
tional parameters of receptor coupling are decreasedpears in the arcuate nucleus at the end of gestation and
Role of Dopamine in Pituitary Cell Lineage Development
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by .80% of normal responsiveness (S. Jones and M. G. 1988). The reduced levels of GHRH mRNA and peptide
in hypothalami of DAT2/2 mice suggest that DA playsCaron, unpublished data).
Several mechanisms may explain the effects of DA a modulatory role in the control of GHRH production.
Increased hypothalamic dopaminergic transmission inon lactotroph development. First, Pit-1/GHF1 is down-
regulated in the anterior pituitary of adult DAT2/2 mice. DAT2/2 mice may blunt the supply of GHRH to the ante-
rior pituitary, thereby leading to a failure of somatotrophAlthough this effect may reflect the lossof somatotrophs
and lactotrophs, the contribution of a direct and selec- proliferation and/or maintenance. In addition, because
of the inhibitory effect of SST on GHRH release (Yamau-tive inhibitory effect of DA on Pit-1/GHF1 gene expres-
sion in lactotrophs cannot be excluded. Evidence from chi et al., 1991; Fodor et al., 1994), the increase in SST
mRNA in DAT2/2 mice may enhance the phenotype.transfected cells expressing D2 DA receptors and a
Pit-1/GHF1 reporter gene have suggested the possibility Importantly, the severe impairment in secretagog-
induced GH secretion suggests that hypothalamic DAthat DA controls the expression of this transcription
factor in an inhibitory fashion (Elsholtz et al., 1991). Sec- might affect other GH-controlling factors. The unknown
ligand, which presumably controls pulsatile GH secre-ond, intrapituitary growth factors have been shown to
control proliferation events in the gland. In particular, tion through the GHRH-6 receptor, seems an interesting
possibility (Smith et al., 1996).transforming growth factor a and nerve growth factor,
which are expressed in lactotrophs (Kobrin et al., 1987;
Patterson and Childs, 1994; Missale et al., 1996), pro-
DAT Dwarfism Recapitulates Pituitarymote their proliferation, as shown by the extensive hy-
Dwarfism Modelsperplasia occurring in transgenic mice overexpressing
Mice lacking the DAT show dwarfism. The comparisoneither growth factor (Borrelli et al., 1992; McAndrew et
of the characteristics of these mice with those of otheral., 1995). In addition, nerve growth factor has been
dwarf phenotypes suggests that DAT dwarfism can re-shown to promote differentiation and proliferation of
capitulate these other models.lactotrophs in culture (Missale et al., 1995). Interestingly,
The Snell, Jackson, and Ames dwarf mutants exhibit asecretion of both growth factors is under the inhibitory
virtually identical phenotype with hypoplastic pituitariescontrol of DA (Borgundvaag et al., 1992; Missale et al.,
completely lacking lactotroph, somatotroph, and thyro-1996). The abnormally high dopaminergic tone to the
troph cells (Li et al., 1990). By contrast, while pituitariesanterior pituitary of DAT2/2 mice may result in enhanced
of DAT2/2 dwarf mice show comparable hypoplasia ofinhibition of transforming growth factor a and nerve
the somatolactotroph lineage, they still contain residualgrowth factor production, thus attenuating signals re-
GH- and PRL-positive cells; thyrotrophs are unaffected.quired to generatean appropriatenumber of lactotrophs
This result is in concert with the molecular defects un-during development. Third, the levels of PRL in the pitu-
derlying the different phenotypes. In the Snell and Jack-itary of mice lacking the DAT are conspicuously de-
son mutants, the Pit-1/GHF1 gene is mutated (Li et al.,creased, and this can contribute to the failure of lacto-
1990), and the Ames mouse appears to be the resulttrophs to proliferate. PRL receptors are present in the
of a mutation in a novel homeodomain gene, Prop-1gland, and PRL itself could mediate mitogenic signals
(Sornson et al., 1996), leading toa defect in the activation(Morel et al., 1994). Interestingly, high PRL content pre-
of Pit-1. As a result, the Pit-1/GHF1 dependent lineagessumably underlies the hyperplastic glands of D2 recep-
fail to develop in these three mouse models. In the DATtor-ablated mice (Saiardi et al., 1997).
dwarfism, the Pit-1/GHF1 gene is neither mutated nor
inhibited in the early stages of pituitary developmentThe Dopaminergic Control of Somatotroph
so that the somatolactotroph lineage develops in theseDevelopment Occurs at the Hypothalamic
animals. The Pit-1/GHF1 gene, however, appears to beLevel and Implicates GHRH
down-regulated in the adult gland, presumably as a re-The most unexpected consequence of the increased
sult of increased DA supply to the anterior pituitary, andhypothalamic DA transmission in DAT2/2 mice is the
this could contribute to the impaired development ofsevere alteration in the GH axis. While somatotrophs do
somatolactotrophs in the later stages of pituitary devel-not contain DA receptors, they are under the physiologi-
opment. Residual Pit-1/GHF1 activity, on the otherhand,cal control of hypothalamic GHRH and SST (Muller,
appears to be sufficient to maintain the full complement1987; Frohman et al., 1992). In particular, GHRH tone is
of thyrotrophs.crucial for the production of appropriate numbers of
DAT dwarfism closely resembles lit/lit dwarfism in thesomatotrophs during pituitary development and for nor-
developmental alterations of somatotrophs (Lin et al.,mal somatic growth rate. DA may participate in the con-
1993). In bothstrains, an initial population of GH-positivetrol of the release of these two hypothalamic hormones,
cells develops, but then they fail to proliferate and mi-however, this point remains controversial (Wass, 1983;
grate within the gland. Both strains are generated by aMuller, 1987). Here, we report that mice lacking the DAT
defect in the GHRH axis, with the lit/lit mouse resultingshow a sizable reduction in the expression and peptide
from a mutation of the GHRH receptor gene (Lin et al.,levels of hypothalamic GHRH. While we have not deter-
1993) and the DAT mouse from an abnormally high sup-mined the locus of these changes in GHRH in hypothala-
pression of GHRH expression by DA due to ablation ofmus, murine GHRH neurons have been localized primar-
the DAT gene. The lit/lit model was the first to directlyily to the arcuate nucleus (Suhr et al., 1989). This nucleus
establish the physiological role of GHRH in somatotrophsends projections to the median eminence (Sawchenko
cell proliferation and migration. The DAT dwarf modelet al., 1985), and it appears to be responsible for regulat-
ing GH release from the pituitary (Chomczynski et al., emphasizes a crucial role of dopaminergic control in
Neuron
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(1 mM) was used to determine nonspecific binding. Incubations wereGHRH expression for the generation of a full comple-
stopped by rapid filtration (Cell HarvesterM-48R, Brandel Co., Gaith-ment of somatotrophs in the adult pituitary and for nor-
ersburg) through Whatman GF/C filters that were counted in an LKBmal somatic growth. Variations in dopaminergic trans-
g-counter. In autoradiography studies, frontal pituitary sections (10
mission, whether pharmacological (cocaine) or as a mm) were thaw mounted on SuperFrost (Fisher) microscope slides
result of central nervous system disorders, could under- and incubated with [125I]NCQ 298 as previously described. Incuba-
tion was stopped by two 2 min rinses in ice-coldphosphate-bufferedlie alterations in somatic growth that are not related to
saline followed by a rapid dipping into ice-cold distilled water. Sec-genetic defects in the hypothalamopituitary axis (Fulroth
tions were allowed to dry for 12 hr and exposed to Kodak BioMaxet al., 1989). The DAT mouse represents the first example
films for 2 days. Films were analyzed by computer-assisted videoof dwarfism generated by alterations in brain neuro-
densitometry, and the binding data were determined from optical
transmission rather than by mutations of genes specifi- density.
cally involved in the pituitary GH axis, and this model
underscores a crucial role for DA in the regulation of GH, PRL, TSH, GHRH, Somatostatin, and Thyroid
Hormone Levelspituitary development.
Wild-type and DAT2/2 animals were divided into groups and treated
either with saline, (2)sulpiride (30 mg/kg), or clonidine (250 mg/Conclusions
kg)±dexamethasone (10 mg/kg). Mice treated with (2)sulpiride or
clonidine±dexamethasone were killed 1 or 2 hr, repectively, after
The DAT2/2 mouse establishes a crucial role for this injection. Blood was collected, and the serum was analyzed for GH
transporter in the dopaminergic control of the ontogeny and PRL contents. For the determination of intrapituitary hormone
content, pituitary extracts were obtained by sonicating tissues inand maintenance of pituitary function. It is now clear
phosphate-buffered saline.For PRLdetermination, only female micethat DA not only controls secretory mechanisms in the
were used. GH and PRL concentrations were determined by radio-adult pituitary, but it also modulates downstream molec-
immunoassay (RIA). The sensitivities of the RIAs were 0.1 ng and
ular and cellular events that regulate proliferation, migra- 0.3 ng for GH and PRL, respectively. Intra- and interassay variabili-
tion, and/or maintenance of cells of the somatolacto- ties were ,5% and ,10%, respectively. Thyroid hormone blood
troph lineage. In the present study, the impact of levels (T3 and T4) were measured by using T3 and T4 RIA kits
from ICN Pharmaceuticals (Costa Mesa, CA). TSH blood levels weredopaminergic transmission on these developmental
measured by RIA.events is evidenced by the combined hypoplasia of so-
matotrophs and lactotrophs, leading to dwarfism and
In Situ Hybridizationfailure to lactate. Moreover, in the accompanying study,
In situ hybridization was performed using oligonucleotide probes
removal of DA action at the pituitary by D2 receptor for determination of PRL and GH mRNA and cRNA probes for Pit-
ablation leads to selective lactotroph hyperplasia and 1/GHF1, b-TSH, and a-GSU mRNA levels. A 45-mer oligonucleotide
tumor formation (Saiardi et al., 1997). complementary to mouse PRL mRNA (59 CATGCCCTCTAGAAGCC
GTTTGGTTTGCTCCTCAATCTCTACAGC 39) and a 42-mer oligonu-
cleotide complementary to GH mRNA (59 GGTCTGCTTGAAGATCTGExperimental Procedures
CCCCCGGGGGCTGCCATCTTCCAG 39) were synthesized and
purified by polyacrylamide gel electrophoresis. The oligonucleotidesGeneration of DAT2/2 Mice
were labeled at the 39 end with [35S-a]dATP (Amersham); slides wereThe DAT2/2 mice were generated as previously described (Giros et
incubated at 378C overnight and washed under stringent conditionsal., 1996). Offspring from heterozygote crossings remained in the
(twice in 13 SSC for 10 min at room temperature, twice in 13 SSCsame cage until weaning. Mice were then genotyped by Southern
at 558C, and once in 13 SSC for 5 min at room temperature) asblot analysis of tail biopsies as described (Giros et al., 1996). They
described by Rattray et al. (1994). In situ hybridization with ribo-were separated in different cages according to sex and genotype,
probes was carried out according to Bendotti et al. (1990). Theand maintained under standard housing conditions. Food and water
riboprobes were labeled using [a-35S]UTP (Amersham); slides werewere provided ad libitum. Animal care was in accordance with the
incubated overnight at 558C and then washed under stringent condi-Guide for Care and Use of Laboratory Animals (NIH publication
tions (13 SSC containing 10 mM 2-mercaptoethanol for 30 min at865±23, Bethesda, MD) and approved by the Institutional Animal
room temperature, RNase buffer containing 20 mg/ml RNase A forCare and Use Committee.
30 min at 378C, the same buffer without RNase at 378C for 30 min,
13 SSC at room temperature for 30 min, 0.53 SSC for 30 min atHPLC Determination of DA and Its Metabolites
658C, and 0.53 SSC for 30 min at room temperature) and dried. TheHypothalami and pituitaries were homogenized in 0.1 N HClO4 con-
slides were exposed to Kodak X-Omat film for autoradiography.taining 100 ng/ml 3,4-dihydroxybenzylamine (internal standard) and
Exposure was for 3 days with Pit-1/GHF1 and a-GSU probes, 7 dayscentrifuged at 15,000 3 g for 20 min. Supernatants were diluted
for b-TSH, and 2 days for PRL and GH. Sections were then dipped1:5 in HPLC buffer (17.5% methanol, 0.15 g/L octylsulfate, 0.1 M
in Kodak K5 emulsion (diluted 1:1 with BIS-distilled water), exposedNa2HPO4, and 0.5 mM EDTA [pH 3.6]), and 100 ml samples were
for 3 weeks at 48C, developed, stained with thionin, and examinedinjected onto an HPLC system (column: Phenomenex C18, 5 m, 15
by dark-field microscopy. Control sense RNA probes were usedcm) coupled to an electrochemical detector (Bioanalytical Systems,
to hybridize adjacent sections as a negative control; no specificWest Lafayette, IN; 10.7 V) and eluted isocratically. DA, DOPAC,
hybridizations were detected.and HVA concentrations were assessed by interpolation to specific
standard curves. The sensitivity of the system was 25 pg for DA
and 10 pg for both HVA and DOPAC. RNA Preparation and Northern Blot Analysis
Total RNA from mouse hypothalami was isolated according to
Chomczynski and Sacchi (1987). Northern blot analysis was per-D2 Receptor Binding Assay and Autoradiography
The highly selective D2 antagonist NCQ 298 (Hall et al., 1991), kindly formed according to Fumagalli et al. (1996) using [32P]cRNA probes
for SST and GHRH mRNAs. Briefly, after prehybridization, mem-provided by Astra Pharmaceutical (Sweden), was iodinated by the
IodoGen method (Fracker and Speck, 1978) to a specific activity of branes were hybridized overnight at 658C, washed under high strin-
gent conditions (23 SSC±0.1% SDS for 30 min at room temperature2000 Ci/mmol. The pituitary D2 receptor density was determined
from the specific binding with two concentrations (100 pM and 250 followed by two to three washes in 0.13 SSC±0.1% SDS for 30 min
at 688C), and then exposed to Kodak X-Omat films. Blots werepM) of radioligand. Binding to purified membrane preparations was
performed in phosphate-buffered saline (150 mM NaCl, 20 mM KCl, quantified using a Molecular Dynamics Phosphorimager (Sunnyvale,
CA) and ImageQuant 3.3 software. A 115-base cRNA probe from a5 mM CaCl2, and 5 mM MgCl2 [pH 7.4]) for 3 hr at 258C. Spiperone
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pTRIPLEscript vector (Ambion) complementary to 28S rRNA was J.C., Tsuruta, K., and Kebabian, J.W. (1982). Biochemical and physi-
ological studies on the beta-adrenoceptor and the D2 dopamineused as an internal control to correct for gel-loading efficiencies.
receptor in the intermediate lobe of the rat pituitary gland: a review.
Neuroendocrinology 35, 217±224.Statistical Analysis
Statistical evaluation of the results was performed by Student's Cunnah, D., and Besser, M. (1991). Management of prolactinomas.
t-test. Clin. Endocrinol. 34, 231±235.
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